-

Ataraxis AI to Present Nine Studies at SABCS 2026

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxis will also present clinical trial data on predicting response to neoadjuvant therapy, from the PHERGain trials, along with new research on invasive lobular breast cancer and long-term prognostication using histology-inferred gene expression.

Oral Presentations on December 9

General Session GS1-1 (Hall 1, 9:30 AM CT): External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit in Node-Negative HR+/HER2– Breast Cancer Patients: Analysis of TAILORx

  • Presenter: Nancy Chan, MD (NYU Langone Health)

General Session GS1-2 (Hall 1, 9:30 AM CT): Blinded Validation of a Causal Multi-Modal AI Model in Postmenopausal, Node-Positive, HR+ Breast Cancer: Analysis of SWOG-8814

  • Presenter: Alastair M. Thompson, MD (Indiana University Simon Comprehensive Cancer Center)

Rapid Fire RF3-3 (Stars at Night 1-2, 4:30 PM CT): A Multi-Cohort Comparison of Genomic, Clinical, and AI Models for Recurrence Prediction in Early Breast Cancer

  • Presenter: Lajos Pusztai, MD, DPhil (Yale School of Medicine)

Poster Presentations on December 9

Poster P1-2-10 (Exhibit Hall, 12:30 PM CT): Multi-National External Validation of a Causal Multi-Modal AI Model for Prognosis and Chemotherapy Benefit Prediction in HR+/HER2– Breast Cancer

  • Presenter: Francisco J. Esteva, MD, PhD (Northwell Health)

Poster P2-4-01 (Exhibit Hall, 5:00 PM CT): Multi-Modal AI Incorporating Histology-Inferred Gene Expression Enables Comprehensive Breast Cancer Prognostication Over a 10-Year Horizon

  • Presenter: Kevin Kalinsky, MD, MS (Winship Cancer Institute, Emory University)

Poster P2-4-02 (Exhibit Hall, 5:00 PM CT): Comparison of a Multi-Modal AI Model to the 21-Gene Recurrence Score Assay in an External HR+/HER2– Breast Cancer Cohort

  • Presenter: Mariam Haji (Roswell Park Comprehensive Cancer Center)

Oral Presentation on December 10

Poster Spotlight PS8-8 (Hemisfair 3, 7:00 AM CT): Multi-Modal AI Predicts Neoadjuvant Response and Long-Term Outcomes in HER2+ Early Breast Cancer Treated With Chemotherapy De-Escalation Strategies: Analysis of the PHERGain Trials

  • Presenter: Giulia Notini, MD (IRCCS San Raffaele Hospital, Milan / MEDSIR)

Poster Presentations on December 10

Poster P3-2-25 (Exhibit Hall, 12:30 PM CT): Predicting Neoadjuvant Therapy Response From Breast Cancer Core Biopsies Using Multi-Modal AI

  • Presenter: Frederick M. Howard, MD (University of Chicago)

Poster P3-11-09 (Exhibit Hall, 12:30 PM CT): Artificial Intelligence-Enabled Risk Stratification in Invasive Lobular Breast Cancer

  • Presenter: Albert Grinshpun, MD (Shaare Zedek Medical Center, Jerusalem)

About Ataraxis AI

Ataraxis AI is a clinical AI company building AI-powered tools to personalize cancer care. By integrating routine digital pathology with clinical data, Ataraxis aims to deliver individualized insights into prognosis and treatment benefit across multiple cancer types.

Ataraxis™ Breast is Ataraxis AI's flagship multimodal platform for breast cancer. Delivered as a suite of AI-powered clinical tests, it combines routine digital pathology with clinical data to generate predictions of recurrence risk and therapy response, supporting decision-making across the full continuum of care. The Ataraxis Breast platform was developed using 30,000+ multimodal patient cases and is designed to fit into existing pathology workflows without requiring additional tissue or specialized assays. All Ataraxis Breast tests are offered as laboratory-developed tests through a CLIA-certified and CAP-accredited laboratory. To learn more, visit ataraxis.ai.

Contacts

More News From Ataraxis AI

Ataraxis AI Publishes Landmark Studies Showing Causal AI Predicts Chemotherapy Benefit in Multiple Solid Tumors

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, today announced scientific breakthroughs and validation results of Ataraxis’s AI models. Ataraxis developed breakthrough causal AI methods that learn from large-scale, longitudinal data to predict patient outcomes in counterfactual treatment scenarios. These methods were encompassed in an AI world model called Ataraxis Tau. Ataraxis Tau was applied to breast cancer, developing a model simula...

Ataraxis AI Launches ARC, a Large-Scale Prospective Study Linking AI Model Predictions to Real Patient Outcomes Across Oncology

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced the launch of Ataraxis ARC (the Ataraxis Real-World Clinical Outcomes Registry), a prospective, multi-site, observational study. ARC is a first-of-its-kind prospective study of AI-based tools in oncology, linking AI tool predictions with real-world short- and long-term patient outcomes.ARC will initially enroll approximately 1,000 patients acr...

Ataraxis AI's Laboratory Receives CAP Accreditation and California Clinical Laboratory License

NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced that its laboratory has received accreditation from the College of American Pathologists (CAP) and a clinical laboratory license from the State of California, expanding access to the Ataraxis Breast platform for clinicians and patients across the state.CAP accreditation follows an on-site inspection by practicing pathologists covering clinical...
Back to Newsroom